MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Dorsolateral nigral hyperintensity on 1.5 versus 3T susceptibility-weighted magnetic resonance imaging in neurodegenerative parkinsonism

    B. Heim, A. Grossauer, F. Krismer, W. Poewe, K. Seppi (Innsbruck, Austria)

    Objective: In contrast to their 1.5T counterparts, high field MRI scanners are often unavailable in clinical routine, particularly in primary care facilities and underserved regions.…
  • 2022 International Congress

    Impact on non-motor symptoms, cognition, and QoL after 1-year of DBS for Parkinson’s Disease: An interim report from the ADROIT NAPA sub-study

    M. Poetter-Nerger, S. Groppa, O. Adam, A. Schnitzler, M. Navas Garcia, B. Cheeran, L. Himes, M. Frassica, A. Gharabaghi (Hamburg, Germany)

    Objective: To present the impact on cognition, quality of life, and non-motor symptoms after 1-year of DBS for Parkinson’s Disease through the ADROIT post-market study.…
  • 2022 International Congress

    Paliperidone induced neuroleptic malignant syndrome treated with electroconvulsive therapy and continuous apomorphine: A case report

    M. Gultekin, S. Benli (Kayseri, Turkey)

    Objective: Neuroleptic malignant syndrome (NMS) is a neurological emergency that is often induced by antipsychotic drugs. NMS may be mortal if left untreated. Background: In…
  • 2022 International Congress

    Silencing dopamine neurons during sleep slows disease progression in parkinsonian mice

    C. Meng, G. Cui (Research Triangle Park, USA)

    Objective: To develop a treatment to stop or slow the progression of Parkinson's disease. Background: Parkinson’s disease (PD) is believed to be caused by the…
  • 2022 International Congress

    Neuroanatomical underpinnings of apathy in Parkinson’s Disease

    C. Le Heron, E. Huey, N. Vanegas-Arroyave, Y. Gazes, S. Lee (New Zealand)

    Objective: To investigated the integrity of white matter tracts within basal ganglia-frontal networks in PD patients with and without apathy, and relate these to specific…
  • 2022 International Congress

    The mGlu2 positive allosteric modulator BINA extends enhances low dose L-DOPA anti-parkinsonian action in the MPTP-lesioned marmoset

    C. Kwan, I. Frouni, S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine the effect of positive allosteric modulation of the metabotropic glutamate type 2 (mGlu2) receptor in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset using a low…
  • 2022 International Congress

    Botulinum Toxin Therapy for Medication and DBS Refractory Foot Dystonia of Parkinsonism

    E. Zinoviev, M. Ganapathy, M. Siddiqui (Winston-Salem, USA)

    Objective: To determine efficacy and safety of BTX therapy in patients with medically refractory foot dystonia secondary to Parkinson’s disease (PD) or atypical Parkinsonism (AP)…
  • 2022 International Congress

    A Patient-Centered Outcomes Survey in Parkinson’s Disease: Results of Cognitive Pre-Testing

    D. Shah-Zamora, J. Karl, M. Tosin, G. Pal, G. Stebbins, C. Goetz, L. Verhagen (Chicago, USA)

    Objective: To validate the Rush Parkinson's Disease Patient-Centered Outcomes Questionnaire (RUSH-PCO-Q). Background: The RUSH-PCO-Q aims to address the lack of patient-centered outcomes in the field…
  • 2022 International Congress

    Associations between stimulation-induced gamma entrainment and motor signs of Parkinson’s Disease

    M. Olaru, A. Hahn, J. Anso, C. Oehrn, J. Sermon, R. Bogacz, T. Denison, B. Duchet, S. Little, P. Starr (San Francisco, USA)

    Objective: To determine whether entrainment of endogenous cortical gamma oscillations in patients with Parkinson’s Disease during deep brain stimulation is associated with improved motor fluctuations.…
  • 2022 International Congress

    Predictors of relapse in impulse control disorders in patients with Parkinson’s disease.

    L. Gaibor, D. Vazquez, H. Estrada (CDMX, Mexico)

    Objective: Identify predictors of relapse in impulse control disorders (ICD) in patients with Parkinson's disease. Background: Behaviors that are performed repeatedly, excessively or minimally and…
  • « Previous Page
  • 1
  • …
  • 139
  • 140
  • 141
  • 142
  • 143
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley